Eledon Pharmaceuticals, Inc. financial data

Symbol
ELDN on Nasdaq
Location
19800 Macarthur Blvd., Suite 250, Irvine, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 989 % -33.7%
Debt-to-equity 95.5 %
Return On Equity 30.5 % -89.6%
Return On Assets 9.79 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59.9M shares +51%
Common Stock, Shares, Outstanding 59.9M shares +55.5%
Entity Public Float 64.9M USD +153%
Common Stock, Value, Issued 60K USD +53.8%
Weighted Average Number of Shares Outstanding, Basic 77.2M shares +82.5%
Weighted Average Number of Shares Outstanding, Diluted 77.2M shares +82.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 68.3M USD +110%
General and Administrative Expense 19.6M USD +36.5%
Operating Income (Loss) -24.7M USD -70.5%
Net Income (Loss) Attributable to Parent 14.6M USD +75%
Earnings Per Share, Basic 0 USD/shares +85.9%
Earnings Per Share, Diluted 0 USD/shares +85.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.74M USD -78%
Cash, Cash Equivalents, and Short-term Investments 108M USD +28.7%
Other Assets, Current 10K USD -93.6%
Assets, Current 111M USD +27.7%
Operating Lease, Right-of-Use Asset 773K USD +24.5%
Goodwill 0 USD
Other Assets, Noncurrent 346K USD +35.7%
Assets 145M USD +20.3%
Accounts Payable, Current 5.83M USD +171%
Liabilities, Current 13.7M USD +128%
Deferred Income Tax Liabilities, Net 2.18M USD +24.6%
Operating Lease, Liability, Noncurrent 467K USD +21%
Liabilities 38.9M USD -69.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -48K USD
Retained Earnings (Accumulated Deficit) -373M USD +3.78%
Stockholders' Equity Attributable to Parent 50.3M USD
Liabilities and Equity 145M USD +20.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.1M USD -83.7%
Net Cash Provided by (Used in) Financing Activities 115K USD
Net Cash Provided by (Used in) Investing Activities 3.89M USD -60.2%
Common Stock, Shares Authorized 300M shares +50%
Common Stock, Shares, Issued 59.9M shares +55.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.1M USD -1256%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.74M USD -78%
Deferred Tax Assets, Valuation Allowance 46.4M USD +50.5%
Deferred Tax Assets, Gross 52M USD +41.3%
Operating Lease, Liability 803K USD +22.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -11.2M USD +75%
Lessee, Operating Lease, Liability, to be Paid 893K USD +32.7%
Operating Lease, Liability, Current 336K USD +24.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 293K USD +48.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 403K USD +111%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +330%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 90K USD +400%
Lessee, Operating Lease, Liability, to be Paid, Year Three 293K USD
Deferred Tax Assets, Operating Loss Carryforwards 22.7M USD +25.7%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 6.23M USD +71.4%
Operating Lease, Payments 97K USD -4.9%
Share-based Payment Arrangement, Expense 13.9M USD +69.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%